Active Trials
8
Phase II–III · 6 indications
All Completed
Total Patients
2,879
Enrolled across all arms
94.1% Completion
Trials Hitting Primary EP
7/8
Statistically significant p < 0.05
87.5%
Lowest p-value
0.0001
ONCO-BREAST-401 · PFS
Highly Significant
SAE Rate (pooled)
1.8%
Serious Adverse Events
Monitored
Hazard Ratio Forest Plot — Primary Endpoints
NOVA-LUNG-301Nexavelumab vs Placebo · OS
HR 0.71 [0.62–0.84]
ONCO-BREAST-401Palbocivex · PFS
HR 0.54 [0.44–0.67]
NEURO-ALZ-501Amyluvectide · CDR-SB
Δ–0.45 [–0.88,–0.02]
RHEUM-RA-303Sariluxamab · ACR50
OR 54.2% [0.48–0.69]
CARDIO-HF-202Carvedexin · 6MWD
Δ+68.4m [12.1–124.7]
← Favors Treatment | Favors Control →
Vertical line = null effect
Response Rate Comparison by Trial
Kaplan-Meier — Overall Survival (NOVA-LUNG-301)
Nexavelumab (n=412) — mOS 24.3mo
Placebo (n=206) — mOS 13.1mo
Adverse Events by Trial — All Grades Summary
| Trial | Drug | Indication |
Grade 1 | Grade 2 | Grade 3 | Grade 4 |
SAEs | Deaths on Trial | Status |
| NOVA-LUNG-301 | Nexavelumab | NSCLC |
287 |
198 |
87 |
12 |
34 | 7 |
Completed |
| ONCO-BREAST-401 | Palbocivex | HR+/HER2- BC |
198 |
156 |
68 |
9 |
29 | 3 |
Completed |
| NEURO-ALZ-501 | Amyluvectide | Early AD |
145 |
112 |
54 |
18 |
42 | 4 |
Completed |
| RHEUM-RA-303 | Sariluxamab | RA |
178 |
134 |
49 |
7 |
22 | 1 |
Completed |
| CARDIO-HF-202 | Carvedexin | HFrEF |
89 |
67 |
23 |
3 |
11 | 2 |
Completed |
⚠ Data Notice: All data presented in this dashboard is randomly generated synthetic data created for demonstration purposes by AlphaStatLab. Trial names, drug names, patient counts, efficacy metrics, and adverse event profiles are entirely fictional and do not represent any real clinical trial, approved drug, or patient population. This dashboard is a portfolio sample illustrating the analytical and visualization capabilities of AlphaStatLab. For real clinical data solutions, contact alphastatlab.org.
Methods: Kaplan-Meier survival curves estimated via step-function approximation from synthetic median survival parameters. Forest plot confidence intervals generated from synthetic log-HR ± 1.96×SE. Adverse event proportions derived from synthetic grade distributions. All p-values are illustrative only. Dashboard built with Chart.js v4.4.1.